GA-binding protein alpha: an ETS family member with an important role in prostate cancer

Autor: Sharma, N, Scott, HE, Mills, IG, Massie, CE, Neal, DE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1c47b46dc655db5ed5b5cc7546bbba35
https://ora.ox.ac.uk/objects/uuid:b82fcbdc-dfdf-4d9e-94b6-9575b17a0254

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer

Autor: Patel, KM, Van Der Vos, KE, Smith, CG, Mouliere, F, Tsui, D, Morris, J, Chandrananda, D, Marass, F, Van Den Broek, D, Neal, DE, Gnanapragasam, VJ, Forshew, T, Van Rhijn, BW, Massie, CE, Rosenfeld, N, Van Der Heijden, MS

Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve a 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant DNA (mutDNA) may allow non-invasive identificati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb671439a002bfb3b23da62a3691667c

Prostate cancer detection through unbiased capture of methylated cell-free DNA.

Autor: Lleshi E; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK.; Department of Engineering, University of Cambridge, Cambridge, UK., Milne-Clark T; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK., Lee Yu H; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK., Martin HW; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK., Hanson R; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK., Lach R; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK., Rossi SH; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK., Riediger AL; University Hospital Heidelberg, 69120 Heidelberg, Germany.; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany., Görtz M; University Hospital Heidelberg, 69120 Heidelberg, Germany., Sültmann H; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany., Flewitt A; Department of Engineering, University of Cambridge, Cambridge, UK., Lynch AG; School of Mathematics and Statistics, University of St Andrews, St Andrews KY16 9SS, UK.; School of Medicine, University of St Andrews, St Andrews KY16 9TF, UK., Gnanapragasam VJ; Department of Surgery, University of Cambridge, Addenbrooke's Hospital Site, Cambridge, UK., Massie CE; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK., Dev HS; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK.

Publikováno v: IScience [iScience] 2024 Jun 20; Vol. 27 (7), pp. 110330. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024).

Genomic evolution shapes prostate cancer disease type.

Autor: Woodcock DJ; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK., Sahli A; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK., Teslo R; Big Data Institute, University of Oxford, Oxford, UK., Bhandari V; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Gruber AJ; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK; Department of Biology, University of Konstanz, Konstanz, Germany., Ziubroniewicz A; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK., Gundem G; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK; Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Xu Y; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK., Butler A; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK., Anokian E; The Institute of Cancer Research, London, UK., Pope BJ; Melbourne Bioinformatics, University of Melbourne, Melbourne, VIC, Australia; Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia; Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia., Jung CH; Melbourne Bioinformatics, University of Melbourne, Melbourne, VIC, Australia., Tarabichi M; The Francis Crick Institute, London, UK; Institute of Interdisciplinary Research (IRIBHM), Universite Libre de Bruxelles, Brussels, Belgium., Dentro SC; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK; The Francis Crick Institute, London, UK., Farmery JHR; Statistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK., Van Loo P; The Francis Crick Institute, London, UK; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Warren AY; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Gnanapragasam V; Cambridge Urology Translational Research and Clinical Trials Office, Addenbrooke's Hospital, Cambridge, UK; Division of Urology, Department of Surgery, University of Cambridge, Cambridge, UK; Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Hamdy FC; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Bova GS; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Tays Cancer Center, Tampere University Hospital, Tampere, Finland., Foster CS; HCA Laboratories, London, UK., Neal DE; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, UK; Department of Surgical Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Lu YJ; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Kote-Jarai Z; The Institute of Cancer Research, London, UK., Fraser M; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Bristow RG; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; CRUK Manchester Institute, University of Manchester, Manchester, UK; Manchester Cancer Research Centre, University of Manchester, Manchester, UK., Boutros PC; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Departments of Human Genetics and Urology, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA., Costello AJ; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia., Corcoran NM; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia., Hovens CM; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia., Massie CE; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, UK; Early Detection Programme and Urological Malignancies Programme, Cancer Research UK Cambridge Centre, Department of Oncology, University of Cambridge, Cambridge, UK., Lynch AG; Statistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK; School of Medicine/School of Mathematics and Statistics, University of St Andrews, St Andrews, UK., Brewer DS; Norwich Medical School, University of East Anglia, Norwich, UK; Earlham Institute, Norwich, UK. Electronic address: d.brewer@uea.ac.uk., Eeles RA; The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: ros.eeles@icr.ac.uk., Cooper CS; The Institute of Cancer Research, London, UK; Norwich Medical School, University of East Anglia, Norwich, UK. Electronic address: colin.cooper@uea.ac.uk., Wedge DC; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK; Manchester Cancer Research Centre, University of Manchester, Manchester, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK; Manchester NIHR Biomedical Research Centre, Manchester, UK. Electronic address: david.wedge@manchester.ac.uk.

Publikováno v: Cell genomics [Cell Genom] 2024 Mar 13; Vol. 4 (3), pp. 100511. Date of Electronic Publication: 2024 Feb 29.